FINWIRES · TerminalLIVE
FINWIRES

Samsung Electronics, Harvard Medical School Affiliate MGH to Study GLP-1 Treatment Effects Using Galaxy Watch

By

Samsung Electronics (KRX:005930) and Harvard Medical School affiliate Massachusetts General Hospital (MGH) will jointly track and analyze physical changes in patients taking glucagon-like peptide-1 (GLP-1) class treatments with the help of the Galaxy Watch.

GLP-1 is an intestinal hormone that helps regulate blood sugar and suppress appetite, Samsung Electronics said in a Thursday release.

The study will assess whether data from the Galaxy Watch 8 and Samsung Health can help manage muscle loss in patients who take GLP-1 drugs by tracking body composition, activity, and heart rate, according to the release.

Shares of Samsung Electronics fell over 2% at market close.

Related Articles

Asia

LG Display Begins Commercial Production of 240Hz RGB Stripe OLED Panels

LG Display (KRX:034220) began the mass production of 240Hz red, green, and blue (RGB) stripe OLED panels, the display maker said in a Thursday release.The panels are optimized for both gaming and office use, according to the release.The display maker plans to expand its OLED monitor lineup with the mass production of 27-inch models alongside key global brands, with an aim to strengthen its presence in the premium monitor market, it said.Shares of LG Display added over 2% at market close.

$KRX:034220
Asia

Center Power Tech Denies AI Hype, Tech Giant Ties

Shenzhen Center Power Tech (SHE:002733) dismissed online rumors that falsely positioned the company as a "core supplier" of artificial intelligence computing infrastructure and claimed ties to Nvidia, Microsoft and Huawei.The company said it has no cooperation with any of those tech giants and does not engage in AI chips, servers or computing platforms, according to a Thursday filing with the Shenzhen bourse.The manufacturer of valve-regulated lead acid batteries urged investors to ignore unverified rumors.Shares of Shenzhen Center Power Tech closed 2% higher Thursday.

$SHE:002733
Asia

Ocumension Therapeutics Enrolls First Patient in Presbyopia Drug Trial

Ocumension Therapeutics (HKG:1477) enrolled the first patient in a phase III clinical trial of OT-802 (pilocarpine hydrochloride) in China, according to a Thursday Hong Kong bourse filing.The drug has been developed for the treatment of presbyopia, the ophthalmic pharmaceuticals maker said.

$HKG:1477